2024
Addressing Disparities in Adolescent and Young Adult Oncology: A Multifaceted Approach.
Puthenpura V. Addressing Disparities in Adolescent and Young Adult Oncology: A Multifaceted Approach. Journal Of The National Comprehensive Cancer Network 2024, 22: 508-510. PMID: 39236751, DOI: 10.6004/jnccn.2024.7062.Peer-Reviewed Original Research
2023
Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
Vieira A, Puthenpura V, Krailo M, Fallahazad N, Brougham M, Murray M, Frazier A, Lopes L, Pashankar F. Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium. Pediatric Blood & Cancer 2023, 70: e30426. PMID: 37243320, DOI: 10.1002/pbc.30426.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaOverall survivalImmature teratomaPostoperative chemotherapyBrazilian patientsStage IIAdjuvant chemotherapyUK cohortGrade 1 diseaseGrade 3 patientsReceipt of chemotherapyMainstay of therapyValue of chemotherapyPrimary outcome measureClinical trial dataIT patientsEntire cohortUK patientsRelapse riskBrazilian cohortOutcome measuresPractice variationChemotherapyPatientsStage ILoss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group
Puthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group. Cancer 2023, 129: 1547-1556. PMID: 36813754, PMCID: PMC10357561, DOI: 10.1002/cncr.34701.Peer-Reviewed Original ResearchConceptsClinical trial participantsNon-Hispanic blacksTrial participantsHazard ratioOncology GroupClinical trialsMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelChildren's Oncology Group trialsProportional hazards regression modelsYoung adultsAdjusted hazard ratioChildren's Oncology GroupLong-term complicationsLong-term outcomesLog-rank testHazards regression modelsPediatric clinical trialsCancer clinical trial participantsLow socioeconomic status areasLong-term survivalEthnic minority patientsQuality of lifeLow socioeconomic statusNon-Hispanic whites
2021
Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors
Berkman A, Andersen C, Puthenpura V, Livingston J, Ahmed S, Cuglievan B, Hildebrandt M, Roth M. Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiology 2021, 75: 102044. PMID: 34597882, PMCID: PMC8627460, DOI: 10.1016/j.canep.2021.102044.Peer-Reviewed Original ResearchConceptsLong-term survivalDLBCL survivorsLymphoma survivorsSurvival disparitiesDiffuse Large B-Cell Lymphoma SurvivorsNon-Hispanic black survivorsNon-Hispanic white survivorsWorse long-term survivalReduced long-term survivalEnd Results registryOverall survival patternsRace/ethnicityMedian followMale sexWhite survivorsOlder ageSurvivorsRacial disparitiesYoung adultsBlack survivorsSocioeconomic statusSurvivalSurvival patternsSexCurrent study
2016
Spinal cord glioblastoma: 25years of experience from a single institution
Yanamadala V, Koffie R, Shankar G, Kumar J, Buchlak Q, Puthenpura V, Frosch M, Gudewicz T, Borges L, Shin J. Spinal cord glioblastoma: 25years of experience from a single institution. Journal Of Clinical Neuroscience 2016, 27: 138-141. PMID: 26755453, DOI: 10.1016/j.jocn.2015.11.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemoradiotherapyCombined Modality TherapyDNA MethylationFemaleGlioblastomaHumansKarnofsky Performance StatusMaleMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalProto-Oncogene Proteins B-rafRecovery of FunctionSpinal Cord NeoplasmsSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53ConceptsHigh-grade spinal cord gliomasSpinal cord gliomasKarnofsky performance statusFunctional statusAmerican Spine Injury Association (ASIA) scorePost-operative functional statusPost-operative radiationSubtotal surgical resectionSubset of patientsTumor recurrence rateYear survival rateTargeted molecular therapiesHigh-grade gliomasAdjuvant chemotherapyPerformance statusSurgical resectionPrimary outcomeRecurrence rateSingle institutionExcellent survivalSpinal cordPatientsAssociation scoreGrade gliomasSurvival rate